The historical rank and industry rank for Nanoform Finland's FCF Margin % or its related term are showing as below:
STU:4YL'
s FCF Margin % Range Over the Past 10 Years
Min: -15665.31 Med: -849.88 Max: -450.18
Current: -450.18
During the past 10 years, the highest FCF Margin % of Nanoform Finland was -450.18%. The lowest was -15665.31%. And the median was -849.88%.
STU:4YL's FCF Margin % is ranked worse than 70.59% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs STU:4YL: -450.18
Nanoform Finland FCF Margin % Related Terms
Nanoform Finland FCF Margin % Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4YL vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Nanoform Finland's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanoform Finland (STU:4YL) has a FCF Margin % of -294.98% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nanoform Finland and its competitors. According to the industry distribution chart, Nanoform Finland ranks #677 out of 959 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Nanoform Finland's FCF Margin % too high?
Nanoform Finland's current FCF Margin % is -294.98%. Based on the distribution chart, Nanoform Finland ranks #677 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #677 out of 959 companies for FCF Margin %. This places Nanoform Finland in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nanoform Finland and its competitors. Nanoform Finland's current FCF Margin % is -294.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (STU:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.82, compared to a current price of €0.77 — trading 57.5% below its estimated fair value. The current FCF Margin % is -294.98%. Nanoform Finland's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nanoform Finland (STU:4YL), the current FCF Margin % is -294.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (STU:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.77 is trading 57.5% below its estimated GF Value™ of €1.82.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for STU:4YL:
FCF Margin %: -294.98%
GF Value™: €1.82 vs. price of €0.77 (57.5% below fair value)
No single metric tells the full story. See the STU:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
68GF Score
Get the complete analysis for STU:4YL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YL has been successfully added to your 
